Ra Capital Management as of Sept. 30, 2023
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 65 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Ascendis Pharma A S (ASND) | 19.9 | $1.0B | 11M | 93.64 | |
Legend Biotech 2 Adr Rep Ord (LEGN) | 8.3 | $421M | 6.3M | 67.17 | |
Vaxcyte Sponsored Ads (PCVX) | 8.0 | $402M | 7.9M | 50.98 | |
ImmunoGen | 4.2 | $211M | 13M | 15.87 | |
89bio (ETNB) | 3.5 | $176M | 11M | 15.44 | |
Biogen Sponsored Adr (BIIB) | 2.7 | $137M | 533k | 257.01 | |
Rhythm Pharmaceuticals (RYTM) | 2.6 | $130M | 5.7M | 22.93 | |
Aerovate Therapeutics (AVTE) | 2.2 | $112M | 8.3M | 13.57 | |
Cymabay Therapeutics | 2.1 | $104M | 6.9M | 14.91 | |
Verona Pharma Plc ads (VRNA) | 2.0 | $103M | 6.3M | 16.30 | |
Tyra Biosciences (TYRA) | 2.0 | $100M | 7.2M | 13.77 | |
Wave Life Sciences (WVE) | 2.0 | $99M | 17M | 5.75 | |
Geron Corporation (GERN) | 1.9 | $98M | 46M | 2.12 | |
Day One Biopharmaceuticals I (DAWN) | 1.9 | $96M | 7.8M | 12.27 | |
Janux Therapeutics (JANX) | 1.8 | $92M | 9.2M | 10.08 | |
An2 Therapeutics (ANTX) | 1.8 | $89M | 5.6M | 16.08 | |
Inhibrx SH | 1.7 | $87M | 4.7M | 18.35 | |
Rxsight (RXST) | 1.7 | $85M | 3.1M | 27.89 | |
Newamsterdam Pharma Co Nv Ord Shs (NAMS) | 1.7 | $83M | 9.0M | 9.25 | |
Evolent Health (EVH) | 1.5 | $75M | 2.7M | 27.23 | |
Curevac N V (CVAC) | 1.4 | $72M | 11M | 6.83 | |
Axsome Therapeutics Class A Ord Shs (AXSM) | 1.4 | $70M | 1.0M | 69.89 | |
Cogent Biosciences (COGT) | 1.2 | $63M | 6.4M | 9.75 | |
Acumen Pharmaceuticals Common Stock (ABOS) | 1.2 | $62M | 15M | 4.15 | |
Taysha Gene Therapies (TSHA) | 1.2 | $58M | 19M | 3.16 | |
Gh Research Sponsored Adr (GHRS) | 1.1 | $56M | 5.6M | 10.05 | |
Alpine Immune Sciences | 1.1 | $54M | 4.7M | 11.45 | |
4d Molecular Therapeutics In (FDMT) | 1.1 | $53M | 4.2M | 12.73 | |
Fulcrum Therapeutics (FULC) | 1.0 | $52M | 12M | 4.44 | |
Iteos Therapeutics (ITOS) | 1.0 | $48M | 4.4M | 10.95 | |
Vor Biopharma (VOR) | 1.0 | $48M | 23M | 2.12 | |
Icosavax | 0.9 | $46M | 6.0M | 7.75 | |
Acrivon Therapeutics (ACRV) | 0.9 | $46M | 4.8M | 9.56 | |
Apogee Therapeutics (APGE) | 0.8 | $42M | 2.0M | 21.30 | |
Pepgen (PEPG) | 0.8 | $41M | 8.1M | 5.08 | |
Avidity Biosciences Ord (RNA) | 0.8 | $41M | 6.4M | 6.38 | |
Soleno Therapeutics (SLNO) | 0.7 | $37M | 1.2M | 29.51 | |
Silverback Therapeutics (SPRY) | 0.7 | $36M | 9.5M | 3.78 | |
Eliem Therapeutics Ads (ELYM) | 0.7 | $35M | 13M | 2.63 | |
Miragen Therapeutics (VRDN) | 0.6 | $31M | 2.0M | 15.34 | |
Pliant Therapeutics (PLRX) | 0.6 | $31M | 1.8M | 17.34 | |
Mineralys Therapeutics (MLYS) | 0.6 | $30M | 3.2M | 9.51 | |
Aclaris Therapeutics Sponsored Ads (ACRS) | 0.6 | $30M | 4.4M | 6.85 | |
Madrigal Pharmaceuticals (MDGL) | 0.6 | $30M | 205k | 146.04 | |
Enliven Therapeutics (ELVN) | 0.6 | $29M | 2.1M | 13.66 | |
Eyepoint Pharmaceuticals (EYPT) | 0.5 | $27M | 3.4M | 7.99 | |
Urogen Pharma (URGN) | 0.4 | $21M | 1.5M | 14.01 | |
Tenaya Therapeutics (TNYA) | 0.3 | $17M | 6.7M | 2.55 | |
Bicycle Therapeutics Plc- Sponsored Adr (BCYC) | 0.3 | $16M | 800k | 20.09 | |
Werewolf Therapeutics (HOWL) | 0.3 | $13M | 6.1M | 2.14 | |
Celcuity (CELC) | 0.3 | $13M | 1.4M | 9.14 | |
Nektar Therapeutics (NKTR) | 0.2 | $11M | 19M | 0.60 | |
Nkarta (NKTX) | 0.2 | $11M | 7.8M | 1.39 | |
Black Diamond Therapeutics (BDTX) | 0.2 | $10M | 3.5M | 2.87 | |
Compass Pathways (CMPS) | 0.2 | $9.5M | 1.3M | 7.40 | |
Solid Biosciences (SLDB) | 0.2 | $8.6M | 3.4M | 2.52 | |
Igm Biosciences (IGMS) | 0.2 | $7.8M | 938k | 8.35 | |
Talaris Therapeutics | 0.1 | $6.8M | 2.4M | 2.81 | |
Chimerix (CMRX) | 0.1 | $6.2M | 6.5M | 0.96 | |
Third Harmonic Bio (THRD) | 0.1 | $6.1M | 962k | 6.39 | |
Connect Biopharma Hldgs (CNTB) | 0.1 | $5.7M | 7.0M | 0.82 | |
Unicycive Therapeutics (UNCY) | 0.1 | $3.0M | 3.5M | 0.86 | |
Nanostring Technologies Ordinary Shares (NSTGQ) | 0.1 | $3.0M | 1.7M | 1.72 | |
Macrogenics (MGNX) | 0.0 | $1.6M | 342k | 4.66 | |
Newamsterdam Pharma Co Nv-27 Ord Shs (NAMSW) | 0.0 | $633k | 333k | 1.90 |